{"filing":{"accession_number":"0001171843-26-004982","cik":"0001069530","ticker":"FLNA","company_name":"FILANA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"f8k_072826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1069530/000117184326004982/f8k_072826.htm"},"events":[{"id":21450,"run_id":19347,"accession_number":"0001171843-26-004982","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The filing discloses Q2 2026 financial results for Filana Therapeutics via a press release attached as Exhibit 99.1, including condensed consolidated statements of operations and balance sheets. The disclosure covers net loss of $8.6 million for Q2 2026, cash position of $82.7 million, R\u0026D and G\u0026A expenses, and cash burn guidance—all hallmarks of a quarterly earnings release. This is material to investors assessing the company's financial condition and runway.","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21100,"accession_number":"0001171843-26-004982","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Filana Therapeutics via a press release attached as Exhibit 99.1, including condensed consolidated statements of operations and balance sheets. The disclosure covers net loss of $8.6 million for Q2 2026, cash position of $82.7 million, R\u0026D and G\u0026A expenses, and cash burn guidance—all hallmarks of a quarterly earnings release. This is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:16:39.432478+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21100,"accession_number":"0001171843-26-004982","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Q2 2026 financial results for Filana Therapeutics via a press release attached as Exhibit 99.1, including condensed consolidated statements of operations and balance sheets. The disclosure covers net loss of $8.6 million for Q2 2026, cash position of $82.7 million, R\u0026D and G\u0026A expenses, and cash burn guidance—all hallmarks of a quarterly earnings release. This is material to investors assessing the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T12:16:39.432478+00:00","company_name":"FILANA THERAPEUTICS, INC.","ticker":"FLNA","filing_date":"2026-07-29"}]}